Abstracts tagged "Outcome measures"

Abstract Number: 0362 • ACR Convergence 2023
Adverse Childhood Experiences Are Associated with Disease Outcomes in Youth with Juvenile Idiopathic Arthritis
Danielle Bullock¹, Ilir Agalliu², Evin Rothschild², Kaveh Ardalan³, Erica Lawson⁴, Natoshia Cunningham⁵, William Soulsby⁴, Nicole Reitz⁶, Laura Bouslaugh⁷, Anna Diggs⁸, Elizabeth Kessler⁹, Sara Kramer¹, Bhupinder Nahal⁴, Cassandra Davis¹⁰, Ashley Kemp¹, Riley O'Connor¹, Tiffany Chinn⁴, Kathy Nguyen⁴, Paige Hill¹ and Tamar Rubinstein¹¹, ¹University of Minnesota, Minneapolis, MN, ²Albert Einstein College of Medicine, Bronx, NY, ³Duke University School of Medicine, Durham, NC, ⁴University of California San Francisco, San Francisco, CA, ⁵Michigan State University, Grand Rapids, MI, ⁶CARRA, Allendale, MI, ⁷CARRA, Washington, DC, ⁸CARRA, Tipton, MO, ⁹Spectrum Health, Grand Rapids, MI, ¹⁰University of Utah, Salt Lake City, UT, ¹¹Albert Einstein College of Medicine, Children's Hospital at Montefiore, White Plains, NY
Background/Purpose: Adverse childhood events (ACEs) are common in children. ACEs are various stressors, including, but not limited to parental incarceration or food and housing insecurity.…
Abstract Number: 0850 • ACR Convergence 2023
Persistence of Urinary Biomarkers of Intrarenal Inflammation Precedes Loss of Kidney Function in Lupus Nephritis
Andrea Fava¹, Mohamed G. Atta¹, Jose Monroy-Trujillo², Derek Fine², Daniel Goldman³, Izmirly peter⁴, H Michael Belmont⁵, the Accelerating Medicines Partnership in RA/SLE⁶, Jill Buyon⁷ and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins School of Medicine, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴NYU, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶Multiple, Multiple, ⁷NYU Grossman School of Medicine, New York, NY
Background/Purpose: One third of lupus nephritis (LN) patients develop irreversible kidney damage despite achieving a clinical response based on resolution of proteinuria. Furthermore, per protocol…
Abstract Number: 1172 • ACR Convergence 2023
Relapse Rate After Glucocorticoid-free Remission in Idiopathic Inflammatory Myopathies with Validation of the International Myositis Assessment & Clinical Studies Group (IMACS) Criteria for Remission and Relapse
Hideaki Tsuji¹, Fabricio Espinosa-Ortega², Maryam Dastmalchi², Ingrid Lundberg² and Karin Lodin³, ¹Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Huddinge, Sweden
Background/Purpose: Our aim was to explore whether maintenance of remission in patients with idiopathic inflammatory myopathy (IIM) depends on glucocorticoids (GCs) after achieving remission. Therefor…
Abstract Number: 1438 • ACR Convergence 2023
Efficacy of Guselkumab in Early-Onset and Late-Onset Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials in Patients with Active PsA
Enrique Soriano¹, Mitsumasa Kishimoto², Emmanouil Rampakakis³, Francois Nantel⁴, May Shawi⁵, Frederic Lavie⁶, Philip J. Mease⁷ and Dafna Gladman⁸, ¹Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Kyorin University School of Medicine, Yokohoma, Japan, ³McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁴Nantel Medsci Consult, Consultant, Montreal, QC, Canada, ⁵Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁶The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁷Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Late-onset PsA may be associated with elevated acute phase reactants, higher joint count, and erosive disease at diagnosis1,2. Given potential phenotype differences and increasing…
Abstract Number: 1827 • ACR Convergence 2023
Revolutionizing Fibromyalgia Treatment: Exploring the Efficacy of a New FDA Cleared Photoceutical Device
Timothy Demchak¹, Ernesto Leal-Junior², Neide Ribeiro², Heliodora Casalechi², Douglas Johnson³ and Shaiane Tomazoni⁴, ¹Indiana State University, Terre Haute, IN, ²Nove de Julho University, São Paulo, Brazil, ³Multi Radiance Medical, Solon, OH, ⁴University of Bergen, Bergen, Norway
Background/Purpose: Fibromyalgia syndrome effects 2-8% of the general population and is characterized by specific tender points. FM annual economic impact $12-$14 billion.Current treatments are only…
Abstract Number: 2154 • ACR Convergence 2023
Two-Year Persistence of First-Line Biological or JAK Inhibitor Treatment in Patients with Long-Standing Rheumatoid Arthritis and Failure of Triple Therapy with Synthetic DMARDs
Sebastian Ibanez Vodnizza¹, María Paz Poblete², María Francisca Valenzuela³, María Magdalena Canals², Dominga García² and Carla Jaque³, ¹Clinica Alemana de Santiago / Facultad de Medicina Universidad del Desarrollo-CAS, Santiago, Chile, ²Hospital Padre Hurtado / Facultad de Medicina Universidad del Desarrollo-CAS, Santiago, Chile, ³Hospital Padre Hurtado, Santiago, Chile
Background/Purpose: In Chile, patients with rheumatoid arthritis (RA) can apply to receive state-funded biological or JAK inhibitor treatment if they have failed (defined as a…
Abstract Number: 2476 • ACR Convergence 2023
Defining Cutoffs for Disease Activity States in Systemic Juvenile Idiopathic Arthritis Based on the Systemic Juvenile Arthritis Disease Activity Score
Silvia Rosina¹, Ana Isabel Rebollo Gimenez², Letizia Tarantola¹, Yulia Vyzhga¹, Luca Carlini³, Elisa Patrone⁴, Maria Katsikas⁵, Claudia Saad-Magalhaes⁶, Dalia El-Ghoneimy⁷, Yasser El Miedany⁸, Raju Khubchandani⁹, Priyankar Pal¹⁰, Gabriele Simonini¹¹, Giovanni Filocamo¹², Maurizio Gattinara¹³, Fabrizio De Benedetti¹⁴, Davide Montin¹⁵, Adele Civino¹⁶, Muatasem Alsuweiti¹⁷, Valda Stenevicha¹⁸, Vyacheslav Chasnyk¹⁹, Ekaterina Alexeeva²⁰, Sulaiman Al-Mayouf²¹, Soamarat Vilayuk²², Angela Pistorio²³ and Angelo Ravelli²⁴, ¹IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genova, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ³IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy, ⁴IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genova, Italy, ⁵Hospital de Pediatria Juan P Garrahan, Servicio de Inmunologia/Reumatologia, Buenos Aires, Argentina, ⁶Sao Paulo State University, Botucatu, Brazil, ⁷PAIR Unit, Children's Hospital Ain Shams University, Cairo, Egypt, ⁸Ain Shams University, Italian Hospital St Abbassia, Cairo, Egypt, ⁹SRCC Childrens Hospital, Mumbai, India, ¹⁰Institute of Child Health, Pediatric Medicine, Kolkata, India, ¹¹Rheumatology Unit, ERN ReConnet Center, Meyer Children's Hospital IRCCS, Florence Italy. NeuroFARBA Department, University of Florence, Florence, Italy, ¹²Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Pediatric Rheumatology, Milan, Italy, ¹³Istituto Gaetano Pini, Divisione di Reumatologia, Milan, Italy, ¹⁴Bambino Gesu Children's Hospital, Division of Rheumatology, Rome, Italy, ¹⁵Immunology and Rheumatology Unit, Regina Margherita Children Hospital, Turin, Italy, ¹⁶P.O. Vito Fazzi, Uo Pediatria - Sezione Reumatologia e Immunologia Pediatrica, Lecce, Italy, ¹⁷King Hussein Medical Center, Department of Pediatrics, Amman, Jordan, ¹⁸Department of Paediatrics, Riga Stradins University, Children University Hospital, Riga, Latvia, ¹⁹Saint-Petersburg State Pediatric Medical University, Pediatrics, Saint-Petersburg, Russia, ²⁰Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ²¹King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, ²²Mahidol University Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand, ²³Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ²⁴Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: The systemic Juvenile Arthritis Disease Activity Score (sJADAS) is a composite disease activity (DA) score specifically validated for use in systemic JIA (sJIA), whose…
Abstract Number: 0381 • ACR Convergence 2023
Disease Burden, Patient Experiences, and Unmet Needs in Refractory Rheumatoid Arthritis: Insights from 20 Years of Real-World Data
Kristin Wipfler¹, Bobby Kwanghoon Han², Sofia Pedro³, Urbano Sbarigia⁴, Federico Zazzetti⁵, Anna Sheahan⁶, Iris Lin⁷, Patti Katz⁸, Evo Alemao⁹ and Kaleb Michaud¹⁰, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Washington, Seattle, WA, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁴Janssen Pharmaceutica, Beerse, Belgium, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen, Raleigh, NC, ⁷Janssen, Horsham, PA, ⁸University of California San Francisco, San Rafael, CA, ⁹Janssen Pharmaceuticals, New Hope, PA, ¹⁰University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Despite major advances in RA treatment, a substantial number of patients (estimated at 6-21%1) are refractory to multiple advanced therapies. Well-defined refractory RA (reRA)…
Abstract Number: 0965 • ACR Convergence 2023
Comparing Predictors of DAPSA28, DAPSA66/68 and DAS28-CRP Remission at 6 Months in Bio-naive Patients with Psoriatic Arthritis Initiating a TNFi in Clinical Practice – Results from the EuroSpA Collaboration
Stylianos Georgiadis¹, Louise Linde², Lykke Ørnbjerg¹, Simon Horskjær Rasmussen¹, Johan Askling³, Brigitte Michelsen⁴, Daniela Di Giuseppe³, Johan Karlsson Wallman⁵, Bente Glintborg⁶, Anne Gitte Loft⁷, Miguel Bernardes⁸, Carolina Ochôa Matos⁹, Dan Nordstrom¹⁰, Laura Kuusalo¹¹, Burkhard Moeller¹², Michael Nissen¹³, Bjorn Gudbjornsson¹⁴, Thorvardur Love¹⁵, Florenzo Iannone¹⁶, Tore Kvien¹⁷, Ziga Rotar¹⁸, Isabel Castrejon¹⁹, Gary Macfarlane²⁰, Marleen van de Sande²¹, Merete Hetland¹ and Mikkel Østergaard²², ¹Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ²Rigshospitalet Glostrup, Glostrup, Denmark, ³Karolinska Institutet, Stockholm, Sweden, ⁴Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ⁵Lund University and Skåne University Hospital, Lund, Sweden, ⁶Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, ⁷Aarhus University, Horsens, Denmark, ⁸Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal, ⁹Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ¹⁰Helsinki University Hospital, Helsinki, Finland, ¹¹Centre for Rheumatology and Clinical Immunology, University of Turku and Turku University Hospital, Turku, Finland, ¹²Inselspital - University Hospital Bern, Bern, Switzerland, ¹³Geneva University Hospitals, Geneva, Switzerland, ¹⁴Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ¹⁵Landspitali University Hospital and the University of Iceland, Reykjavik, Iceland, ¹⁶Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁷Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁸University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁹Universitario Gregorio Marañón, Madrid, Spain, ²⁰Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²¹Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ²²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: The Disease Activity index for PSoriatic Arthritis based on 66/68 joints (DAPSA66/68) and the Disease Activity Score in 28 joints with C-reactive protein (DAS28-CRP)…
Abstract Number: 1178 • ACR Convergence 2023
Self-Perceived Knowledge of Myositis Among Social Media Respondents- a Pilot Study on Twitter
Srijan Mittal¹, Vanshita Batra¹, Parikshit Sen², Saadia Sasha Ali³, Arpit Mago⁴, Mark Russell⁵, Eugenia Gkiaouraki⁶ and Rohit Aggarwal⁶, ¹Maulana Azad Medical College, New Delhi, India, ²Maulana Azad Medical College, 2-Bahadurshah Zafar Marg, New Delhi, Delhi-110002, India., Dalhi, India, ³King's College Hospital, Epsom, United Kingdom, ⁴Jawaharlal Nehru Medical College, Belgaum, India, ⁵King's College Hospital, London, United Kingdom, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Myositis is a rare complex autoimmune disease that is less known and poorly understood, with increased effort required for education of practitioners, students, educators,…
Abstract Number: 1453 • ACR Convergence 2023
Musculoskeletal Involvement in Systemic Lupus Erythematosus: Insights from a Survey of Lupus Experts
Rashmi Dhital¹, Maria Dall'Era² and Kenneth Kalunian³, ¹UC San Diego, San Diego, CA, ²University of California San Francisco, San Francisco, CA, ³University of California San Diego, La Jolla, CA
Background/Purpose: Musculoskeletal manifestations of systemic lupus erythematosus (SLE) are common, consisting ofarthralgia and arthritis (95%), myalgia/myositis (17%), tenosynovitis, and bursitis (12%). Joint involvement is a…
Abstract Number: 1840 • ACR Convergence 2023
Value of Various Intra-Articular Injections for Knee Osteoarthritis Management
Hanna Mass¹, Jamie Collins¹, david Hunter², Catherine Yang¹, Morgan Jones¹, Stephen Messier³, Tuhina Neogi⁴, A. David Paltiel⁵, Jeffrey Katz¹ and Elena Losina⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Sydney Musculoskeletal Health, University of Sydney, St. Leonards, Australia, ³Wake Forest University, Winston-Salem, NC, ⁴Boston University School of Medicine, Boston, MA, ⁵Yale School of Public health, New Haven, CT, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Intra-articular injections (IAI) are commonly used to relieve pain and delay total knee replacement (TKR) in persons with knee OA. Despite higher costs and…
Abstract Number: 2216 • ACR Convergence 2023
Hierarchy of Determinants of Work Impairment in Spondyloarthritis: Data from the Assessment of Spondyloarthritis International Society Health Index (ASAS-HI) International Validation Study
Frederico Rajão Martins¹, Pedro Carvalho², Désirée van der Heijde³, Manouk de Hooge⁴, Annelies Boonen⁵, Juergen Braun⁶, Uta Kiltz⁷ and Pedro Machado⁸, ¹Department of Rheumatology, University Hospital Centre of Algarve, Faro, Portugal, ²Hospital Particular do Algarve, Gambelas, Faro. Centro Académico de Lisboa, Lisboa, Portugal, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Ghent University Hospital, Hesperange, Luxembourg, ⁵Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands, ⁶Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany, ⁸Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom
Background/Purpose: Spondyloarthritis (SpA) is a disease of the working-age individual, with diverse economic and societal implications, including decreased employment rates. Our aim was to investigate…
Abstract Number: 2480 • ACR Convergence 2023
Definition of Rheumatoid Arthritis Flare Based on SDAI and CDAI
Victoria Konzett¹, Andreas Kerschbaumer², Josef S Smolen³, Eirik Kristianslund⁴, Sella Provan⁴, Tore Kvien⁵ and Daniel Aletaha⁶, ¹Medical University of Vienna, Wien, Austria, ²Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria
Background/Purpose: Measures of improvement and state of disease activity are well-established in rheumatoid arthritis (RA), whereas distinct classifiers for worsening (“flare”) are lacking to date.…
Abstract Number: 0123 • ACR Convergence 2023
Improving Interpretation of Work Outcomes in Patients with Inflammatory Rheumatic Musculoskeletal Disease: General Population Reference Curves for Work Ability and At-work Productivity
Dafne Capelusnik¹, Wouter Smeets², Casper Webers³, Sofia Ramiro⁴, Elena Nikiphorou⁵, Roel Braekers², Laura Boekel⁶, Gertjan Wolbink⁷ and Annelies Boonen⁸, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Data science institute, Hasselt University, Hasselt, Belgium, ³Maastricht University, Maastricht, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵King's College London, London, United Kingdom, ⁶Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Amsterdam, Netherlands, ⁷Reade, Amsterdam, Netherlands, ⁸Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands
Background/Purpose: Data on self-reported presenteeism (limitations or reduced work productivity at work) in persons with inflammatory rheumatic and musculoskeletal diseases (iRMD) are challenging to interpret…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].